PMID

Data

Article Title

Organization

Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors.

Xenon Pharmaceuticals

4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: part 2. Pyridazine-based analogs.

Janssen Research and Development

Systematic evaluation of amide bioisosteres leading to the discovery of novel and potent thiazolylimidazolidinone inhibitors of SCD1 for the treatment of metabolic diseases.

Xenon Pharmaceuticals

Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effects.

Xenon Pharmaceuticals

4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: urea-based analogs.

Janssen Research and Development

Benzimidazole-carboxamides as potent and bioavailable stearoyl-CoA desaturase (SCD1) inhibitors from ligand-based virtual screening and chemical optimization.

Sanofi-Aventis Deutschland

Discovery of liver-targeted inhibitors of stearoyl-CoA desaturase (SCD1).

Merck Research Laboratories

Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.

Xenon Pharmaceuticals

Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.

Merck Frosst Centre For Therapeutic Research

Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors.

Abbott Laboratories

Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series.

Merck Frosst Centre For Therapeutic Research

Nicotinic acids: liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy.

Merck Frosst Centre For Therapeutic Research

Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series.

Merck Frosst Centre For Therapeutic Research

Conversion of systemically-distributed triazole-based stearoyl-CoA desaturase (SCD) uHTS hits into liver-targeted SCD inhibitors.

Merck Frosst Centre For Therapeutic Research

Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitors.

Merck Frosst Centre For Therapeutic Research

Discovery of novel SCD1 inhibitors: 5-alkyl-4,5-dihydro-3H-spiro[1,5-benzoxazepine-2,4'-piperidine] analogs.

Daiichi Sankyo

N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors.

Pfizer

Synthesis and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4'-piperidine] analogs.

Daiichi Sankyo

2-Aryl benzimidazoles: human SCD1-specific stearoyl coenzyme-A desaturase inhibitors.

Merck Frosst Centre For Therapeutic Research

SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors.

Merck Frosst Centre For Therapeutic Research

Novel spiropiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-5-(trifluoromethyl)-3,4-dihydrospiro[chromene-2,4'-piperidine].

Daiichi Sankyo

Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).

Merck Frosst Centre For Therapeutic Research

Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide and its plasma triglyceride-lowering effects in Zucker fatty rats.

Daiichi Sankyo

Thiazole analog as stearoyl-CoA desaturase 1 inhibitor.

Merck Frosst Centre For Therapeutic Research

Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.

Gilead Sciences

Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part I: Discovery of 3-(2-hydroxyethoxy)-4-methoxy-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide.

Daiichi Sankyo

Novel and potent inhibitors of stearoyl-CoA desaturase-1. Part II: Identification of 4-ethylamino-3-(2-hydroxyethoxy)-N-[5-(3-trifluoromethylbenzyl)thiazol-2-yl]benzamide and its biological evaluation.

Daiichi Sankyo

Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.

Cv Therapeutics

Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors.

Abbott Laboratories

Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.

Central South University

T-3364366 Targets the Desaturase Domain of Delta-5 Desaturase with Nanomolar Potency and a Multihour Residence Time.

Takeda Pharmaceutical

Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.

Japan Tobacco

Probing the peripheral site of human butyrylcholinesterase.

Dalhousie University

Novel structure having antagonist actions at both the glycine site of the N-methyl-D-aspartate receptor and neuronal voltage-sensitive sodium channels: biochemical, electrophysiological, and behavioral characterization.

University of Colorado